Phase III success for Regeneron signals pozelimab and cemdisiran’s entry into MG market

Regeneron’s pozelimab and Alnylam Pharmaceuticals’ cemdisiran work through mediating C5 complement inhibition.
TipRanks on MSN

Larimar announces 25 mg, 50 mg data from OL study of nomlabofusp

Larimar Therapeutics (LRMR) announced 25 mg and 50 mg data from the ongoing long-term open label study evaluating daily subcutaneous injections of ...
Nasdaq

Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular ...

SCOTTSDALE, Ariz., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage biopharmaceutical company that focuses on the development and ...
Robb Report

First Drive: These Stunning MGB Restomods Come With a V-8 or Electric Motor. We Tested Both.

As a Brit and a car enthusiast, I should probably love the MGB too. But I grew up in the 1980s, when hot hatchbacks like the Golf GTI made the homegrown roadsters my father lusted after seem instantly ...
BioSpace

Ionis Heads to FDA as Antisense Therapy Aces Pivotal Study in Rare Neurological Disease

By improving gait stability, Ionis’ zilganersen could be “potentially disease modifying,” according to analysts at William ...
Road & Track

For $223,000, the Frontline LE60 Restomod Nearly Perfects the MGB GT

I hear the Frontline LE60 before I see it. A small enclosed trailer quakes to its V-8 soundtrack and it gradually backs down the ramps and reveals itself to an otherwise unremarkable day in the U.K.
The Lancet

ATG as disease-modifying therapy for new-onset type 1 diabetes

Type 1 diabetes remains a persistent health-care burden despite substantial advances in care. Its preclinical disease course ...